Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 0.8% Since Last Earnings Report?

Merck's shares are up 6.2% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

Merck (MRK) Up This Year So Far: Will the Momentum Continue?

Boston Scientific

Johnson & Johnson

Pfizer

U.S. equities are mostly higher in post-holiday trading on Tuesday, as investors are looking for stocks to buy.

4 Drug and Health Stocks Pushing Higher  

Bristol-Myers

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy.

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

The acquisition can strengthen Merck's presence in the field of renal cell carcinoma and bolster its cancer drug portfolio.

Merck buys Peloton Therapeutics to expand its kidney cancer treatment portfolio

Dow Jones component Merck will spend up to $2.2 billion to buy privately held biotech Peloton Therapeutics for its cancer treatments. Peloton's latest-stage effort is a kidney cancer drug.

Merck To Acquire Cancer Biotech In Deal Worth Up To $2.2 Billion

Merck & Co., Inc. announced an agreement Tuesday to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion in if certain regulatory and sales milestones are reached.

Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B

U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate.

Merck buys Peloton to expand its kidney cancer treatment portfolio

Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company's renal cancer drug candidate.

Merck to buy cancer drug developer Peloton for $1.05 billion in cash

Merck & Co. Inc. MRK, +0.20% said Tuesday it has reached an agreement to acquire Peloton Therapeutics Inc.

Merck to acquire Peloton Therapeutics for upfront payment of $1.05 billion in cash

Merck & Co. MRK, +0.20% shares slipped in the extended session Monday after the drug maker said its cancer treatment Keytruda failed to meet clinical endpoints in another late-stage study.

Merck shares slip as Keytruda fails another clinical trial

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

Why Merck is a Great Dividend Stock

American Express

Cisco Systems

Genuine Parts

Coca-Cola

In this volatile market, blue-chip stocks will get you through. Here are five of the bluest stocks to buy today.

5 Great Blue-Chip Stocks to Buy Today

Atlantic Equities says Merck is the company is "the best positioned" to grow among large pharmaceutical companies.

Merck's stock upgraded on theory drugmaker is 'insulated from trade-related volatility'

The four companies that now dominate global vaccine sales are Merck, Pfizer, Sanofi Pasteur and GlaxoSmithKline.

Top vaccine makers Merck and Pfizer target China and older adults next

Merck has moved up the past few years, due mostly to booming sales of Keytruda, its immune stimulator to treat cancer.

Merck - Reasons To Like The Reward:Risk Ratio

Merck recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecasts for the full year 2019.

Merck's Q1 Earnings Beat Led By Keytruda

Merck stock rebounded after the company reported positive earnings on April 30, helped by a "golden cross" on its daily chart.

Merck Stock Bounces Back Thanks to a 'Golden Cross'

Merck & Co Inc. (MRK) CEO Ken Frazier on Q1 2019 Results - Earnings Call Transcript

Here's why the big drugmaker topped Wall Street's top- and bottom-line estimates for the first quarter.

What You Need to Know About Merck's Great Q1 Earnings Results

Merck (MRK) beats estimates for earnings as well as sales in first-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

Merck (MRK) Beats on Q1 Earnings & Sales as Keytruda Shines

Eli Lilly

Shares of Pfizer and Merck rose after reporting financial results that beat expectations.

Three major pharmaceutical companies just reported earnings — here’s how they did

Merck (MRK) beats estimates for earnings as well as sales in first-quarter 2019. Stock is up in pre-market trading.

Merck (MRK) Tops on Q1 Earnings & Sales, Stock Up

Merck & Co. Inc. shares  rose 2.6% in premarket trade Tuesday, after the drug company posted stronger-than-expected earnings for the first quarter and raised guidance for the full year.

Merck shares rise premarket as earnings top estimates

Amgen

Amarin Corporation Plc

Exact Sciences

If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.

News for Merck Stock (MRK)